Suppr超能文献

头颈部肿瘤的增殖特性。通过溴脱氧尿苷掺入和流式细胞术进行体内评估。

Proliferative characteristics of head and neck tumors. In vivo evaluation by bromodeoxyuridine incorporation and flow cytometry.

作者信息

Benazzo M, Mevio E, Occhini A, Franchini G, Danova M

机构信息

Clinica Otorinolaringoiatrica, University of Pavia, Italia.

出版信息

ORL J Otorhinolaryngol Relat Spec. 1995 Jan-Feb;57(1):39-43. doi: 10.1159/000276705.

Abstract

Cell proliferation of head and neck cancers was studied in 52 patients using in vivo bromodeoxyuridine (BUDR) incorporation. Patients received 250 mg BUDR intravenously several hours prior to biopsy of the tumor tissue. Bivariate flow cytometry was used and enabled us to rapidly obtain DNA ploidy, labelling index (LI), DNA synthesis time (TS) and tumor potential doubling time (Tpot). This method was found to be suitable to obtain complete cytokinetic data in 46/52 (88.5%) patients. The mean BUDR LI was 7.9% (range 2-18%); mean TS was 11.6 h (range 6-28.5 h); mean Tpot was 5.7 days (range 2-30 days). BUDR LI and TS were significantly correlated with histological differentiation grading: G3 tumors showed higher LI values and shorter TS values than G1/G2 tumors. A similar correlation was found between LI or TS and tumor dimensions. Tpot was also significantly lower in larger tumors, such as in those with a higher grading. No significant correlation was found between LI or TS and DNA ploidy (50% of the tumors in our series were DNA aneuploid), while Tpot was found to be 10 days in diploid tumors, compared to only 6.3 days for the aneuploid tumors (p < 0.05). All cases with documented lymph node involvement (N+) showed significantly higher LI, and shorter TS and Tpot values if related to nodal free ones (Tpot = 10 days in N+ patients and 6.3 days in N- patients; p < 0.05). The results of this study suggest that the method employed is clinically feasible and could be a useful aid in defining the prognosis of head and neck cancer patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

采用体内溴脱氧尿苷(BUDR)掺入法,对52例头颈部癌患者的细胞增殖情况进行了研究。患者在肿瘤组织活检前数小时静脉注射250mg BUDR。使用双变量流式细胞术,使我们能够快速获得DNA倍体、标记指数(LI)、DNA合成时间(TS)和肿瘤潜在倍增时间(Tpot)。结果发现,该方法适用于46/52(88.5%)的患者获取完整的细胞动力学数据。平均BUDR LI为7.9%(范围2-18%);平均TS为11.6小时(范围6-28.5小时);平均Tpot为5.7天(范围2-30天)。BUDR LI和TS与组织学分化分级显著相关:G3肿瘤的LI值高于G1/G2肿瘤,TS值短于G1/G2肿瘤。在LI或TS与肿瘤大小之间也发现了类似的相关性。较大肿瘤(如分级较高的肿瘤)的Tpot也显著较低。未发现LI或TS与DNA倍体之间存在显著相关性(我们系列中的50%肿瘤为DNA非整倍体),而二倍体肿瘤的Tpot为10天,非整倍体肿瘤仅为6.3天(p<0.05)。所有有记录的淋巴结受累(N+)病例,如果与无淋巴结受累病例相关,则显示出显著更高的LI、更短的TS和Tpot值(N+患者的Tpot = 10天,N-患者的Tpot = 6.3天;p<0.05)。本研究结果表明,所采用的方法在临床上是可行的,并且可能有助于确定头颈部癌患者的预后。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验